Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicenter Cohort Study of the Multi-omics Liquid Biopsy MCED Test MERCURY in an Average Risk Chinese Population

NCT06011694 is registered in ClinicalTrials.gov with Nanjing Shihejiyin Technology, Inc. as lead sponsor.

NCT NCT06011694
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06011694 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicenter Cohort Study of the Multi-omics Liquid Biopsy MCED Test MERCURY in an Average Risk Chinese Population
Lead sponsor
Nanjing Shihejiyin Technology, Inc.
Phase
Observational
Overall status
Recruiting
Start date
June 15, 2022
Completion date
May 15, 2027
Enrollment
15,000 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, liquid biopsy, multi cancer early screening